TCM
RNTX

Traynor Capital Management’s Rein Therapeutics RNTX Stock Holding History

Traynor Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,000
Closed -$118K – 174
2020
Q2 		$118K Buy
+5,000
New +$81.5K 0.03% 143

Other funds holding RNTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Traynor Capital Management's RNTX Position: Q3 2020 in Review

Traynor Capital Management sold out of Rein Therapeutics (RNTX) in Q3 2020, closing a stake of 5,000 shares — an estimated $118K sold.

Traynor Capital Management first reported a position in RNTX in Q2 2020 and held it in 1 quarter. The position peaked at $118K in Q2 2020. 28 funds tracked by Wall St. Rank hold RNTX as of Q3 2020.

  • Traynor Capital Management reported no remaining Rein Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Traynor Capital Management sold 5,000 Rein Therapeutics shares in Q3 2020, an estimated $118K.
  • Traynor Capital Management first reported a position in Rein Therapeutics in Q2 2020 and held it in 1 quarter.
  • Traynor Capital Management's Rein Therapeutics position peaked at $118K in Q2 2020.
  • 28 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2020.

Based on Traynor Capital Management's 13F filing for Q3 2020, filed 26 Oct 2020.